Indacaterol/glycopyrronium bromide

Indacaterol/glycopyrronium bromide
Combination of
Indacaterol Ultra-long-acting beta-adrenoceptor agonist
Glycopyrronium bromide Muscarinic anticholinergic
Clinical data
Trade names Ultibro Breezhaler, Utibron Neohaler
Routes of
Inhalation only
ATC code R03AL04 (WHO)
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • ℞ (Prescription only)
CAS Number 444313-53-5 YesY
PubChem (CID) 11564052

Indacaterol/glycopyrronium bromide is a combination drug consisting of the following two active ingreditents:

Indacaterol maleate/glycopyrronium bromide is used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).[2]

The drug is marketed by Novartis under the trade names Ultibro Breezhaler and Utibron Neohaler in Europe and the United States, respectively.[2][3]


  1. Cazzola M, Matera MG, Lötvall J (July 2005). "Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease". Expert Opin Investig Drugs. 14 (7): 775–83. doi:10.1517/13543784.14.7.775. PMID 16022567.
  2. 1 2 "Ultibro Breezhaler". DataPharm. 2015-02-03. Retrieved 2015-02-09.
  3. "Approval History: NDA 207930". DRUGS@FDA. US FDA. Retrieved 14 May 2016.

This article is issued from Wikipedia - version of the 11/21/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.